Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Tosufloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | RARB | P10826 | 1/20 | 0.71 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | TOP2A | P11388 | 12/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tosufloxacin SCHEMBL9323984 | 0.96 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL29383684 | 0.96 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL34354 | 0.96 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL34355 | 0.96 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL28308419 | 0.95 | KMT2A (0.98) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL3754459 | 0.95 | KMT2A (0.98) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL19149806 | 0.95 | KMT2A (0.98) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL9691106 | 0.95 | KMT2A (0.98) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL9691051 | 0.92 | KMT2A (0.93) | KMT2AEPHA2FLT4GSK3BRARB | |
| Trovafloxacin SCHEMBL373984 | 0.91 | KMT2A (0.90) | KMT2AEPHA2FLT4GSK3BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |